Spark Therapeutics, Ultragenyx and Others to Headline March 24-26 Meeting in Barcelona
BARCELONA, Spain–(BUSINESS WIRE)–#BPSMTeu–With the global market for gene therapy expected to hit $13 billion (USD) by 2024 (Research And Markets), Bioprocessing Summit Europe is returning March 24-26, 2020 with its popular Gene Therapy CMC and Manufacturing track.
Expanding to a new venue to accommodate increased registrations, the meeting will take place at The Crowne Plaza Barcelona (Spain)–Fira Center.
From the Plenary Keynote by Diane Blumenthal, PhD, Head, Technical Development, Spark Therapeutics, the first company to obtain approval of a gene-therapy product in the EU and US, to insights from Biogen, Sanofi, Vivet Therapeutics, Takeda and Ultragenyx, content will focus on accelerating therapies into the market.
“There is a real thirst for knowledge about how to rapidly deploy biologics while ensuring quality and cost-efficiency. This conference reveals the critical challenges facing the manufacture, analysis and control of these exciting new therapies,” said Dan Barry, Senior Conference Director, CHI.
Among highlights:
- A Keynote by James Warren, PhD, Vice President, Pharmaceutical Development, Ultragenyx, on Rapid CMC Development and Pre-Commercial Considerations for rAAV Gene Therapy Products for Rare Diseases
- More than 15 sessions on Advancing CMC and Analytical Strategies, Optimizing Scale-Up and Process Control, and AAV Purification and Lentiviral Manufacturing
- A short course on Quality Considerations for Gene Therapy Viral Vectors
The event will also include:
- A Plenary Keynote by Ralf Schumacher, PhD, Global Head, Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG
- 130+ presentations on Upstream Processing, Downstream Processing, Analytical and Formulation, Cell Therapy CMC and Manufacturing, and the Gene Therapy content
- Training Seminars, 40 cutting-edge exhibitors, poster sessions and 1-On-1 Networking
About Cambridge Healthtech Institute
Cambridge Healthtech Institute (CHI), a division of Cambridge Innovation Institute, is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech, CROs, academia, and niche service providers. CHI is renowned for its vast conference portfolio held worldwide including PepTalk, Molecular Medicine Tri-Conference, SCOPE Summit, Bio-IT World Conference & Expo, PEGS Summit, Drug Discovery Chemistry, Biomarker World Congress, World Pharma Week, The Bioprocessing Summit, Next Generation Dx Summit, Immuno-Oncology Summit, and Discovery on Target. CHI’s portfolio of products include Cambridge Healthtech Institute Conferences, Barnett International, Insight Pharma Reports, Bio-IT World, Clinical Research News and Diagnostics World.
Contacts
Dawn Ringel
+1-781-449-8456, dawn@ringelpr.com